← Back to guidelines
Dermatology37 papers

Linear IgA dermatosis

Last edited: 4/16/2026

Overview

Linear IgA dermatosis (LAD) is a rare subepidermal autoimmune bullous disease characterized by predominant immunoglobulin A deposits at the basement membrane zone, affecting both children and adults 1.

Diagnosis

  • Clinical Features: Vesicles and bullae, often with mucosal involvement 1.
  • Histopathology: Subepidermal blister formation with IgA deposition at the basement membrane zone on direct immunofluorescence 1.
  • Direct Immunofluorescence: Essential for confirming IgA deposition 1.
  • Indirect Immunofluorescence: Useful for detecting circulating IgA autoantibodies 1.
  • Biopsy: Required for histopathological confirmation 1.
  • Differential Diagnosis: Includes bullous pemphigoid, dermatitis herpetiformis, and other subepidermal blistering disorders 1.
  • Management

  • First-Line Treatments:
  • - Corticosteroids: Topical or systemic, depending on disease severity 1. - Dapsone: Effective for many patients, especially those with mild to moderate disease 1.
  • Adjunctive Treatments:
  • - Immunosuppressants: Azathioprine, mycophenolate mofetil, or ciclosporin for refractory cases 1. - Biologics: TNF-α inhibitors or rituximab considered in severe, refractory cases 1.

    Special Populations

  • Pediatrics: Similar management principles apply, with careful monitoring of growth and development 1.
  • Pregnancy: Management requires careful consideration of teratogenic risks; corticosteroids and dapsone are often used cautiously 1.
  • Elderly: Increased vigilance for side effects of systemic treatments; topical therapy may be preferred initially 1.
  • Comorbidities: Tailor treatment considering potential drug interactions and organ function 1.
  • Key Recommendations

  • Diagnosis should include histopathology and direct immunofluorescence to confirm IgA deposition at the basement membrane zone (Evidence: Expert opinion 1).
  • Topical or systemic corticosteroids are recommended as first-line therapy for LAD (Evidence: Expert opinion 1).
  • Dapsone should be considered for patients with mild to moderate LAD (Evidence: Expert opinion 1).
  • Refractory cases may require immunosuppressive agents such as azathioprine or ciclosporin (Evidence: Expert opinion 1).
  • Management in pregnant patients should prioritize safety, often starting with corticosteroids or dapsone (Evidence: Expert opinion 1).
  • Close monitoring is essential in elderly patients due to increased risk of side effects from systemic treatments (Evidence: Expert opinion 1).
  • References

    1 Caux F, Patsatsi A, Karakioulaki M, Antiga E, Baselga E, Borradori L et al.. S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link

    Original source

    1. [1]
      S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology.Caux F, Patsatsi A, Karakioulaki M, Antiga E, Baselga E, Borradori L et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG